The Architecture of Nocturnal Fear: A Network Pharmacology Approach to Discover Nightmare-Associated Genes
Journal of Molecular Neuroscience · 05.11.2026 · 76 (4)
DOI: 10.1007/s12031-026-02617-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Neuroscience, online erschienen am 05.11.2026. Verfasst von Amirsajad Jafari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. a.sajad.jafari@gmail.com. Hauptthemen laut MEDLINE: Protein Interaction Maps, Fear. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Nightmares impose a substantial burden on mental health, yet their molecular determinants remain poorly understood. We employed a network pharmacology approach to identify shared protein targets of structurally diverse nightmare-inducing drugs. This approach revealed an eight-protein interactome: serotonergic (HTR2A, HTR2C, HTR1A, HTR6, HTR7), dopaminergic (DRD2, DRD3), and the potassium channel KCNH2. Protein-protein interaction networks and Gene Ontology analysis identified DRD2, HTR1A, and HTR2A as central hubs. These genes showed enrichment for neurotransmitter receptor activity and synaptic transmission. Multiple validation approaches provided initial, though not definitive, support for specificity. Negative-control drugs with lower nightmare incidence yielded a distinct intersection (ACHE and CHRM2). Permutation analysis confirmed the eight-protein composition was significantly distinct from random expectation (p = 0.0200). Experimental binding data from ChEMBL and IUPHAR/BPS confirmed high-affinity interactions for clozapine (7/8 targets) and partial support for other drugs. Analysis of nightmare-treating drugs revealed six shared proteins (HTR7, HTR2C, HTR1A, KCNH2, DRD3, DRD2). This suggests a "shared pathway perturbation" framework where directionality of modulation may determine clinical outcome. Brain expression data confirmed that all eight proteins are expressed in regions critical for sleep and emotional regulation. This framework offers a mechanistic basis for understanding nightmare susceptibility and identifies potential targets for intervention, while highlighting the need for prospective experimental validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. a.sajad.jafari@gmail.com.
- Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. a.sajad.jafari@gmail.com.
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Zitieren
APA
Jafari, A., Jahanbakhsh, S., Azadian, S., Sarduiyeh, A. O., & Rajabi, T. (2026). The Architecture of Nocturnal Fear: A Network Pharmacology Approach to Discover Nightmare-Associated Genes. Journal of Molecular Neuroscience, 76(4). https://doi.org/10.1007/s12031-026-02617-7
Vancouver
Jafari A, Jahanbakhsh S, Azadian S, Sarduiyeh AO, Rajabi T. The Architecture of Nocturnal Fear: A Network Pharmacology Approach to Discover Nightmare-Associated Genes. Journal of Molecular Neuroscience. 2026;76(4). doi:10.1007/s12031-026-02617-7
BibTeX
@article{Jafari2026,
author = {Jafari, Amirsajad and Jahanbakhsh, Shayan and Azadian, Shima and Sarduiyeh, Abolfazl Omrani and Rajabi, Tara},
title = {The Architecture of Nocturnal Fear: A Network Pharmacology Approach to Discover Nightmare-Associated Genes},
journal = {Journal of Molecular Neuroscience},
year = {2026},
volume = {76},
number = {4},
doi = {10.1007/s12031-026-02617-7}
}
EUVIMED